Most data on FGF21 signaling in WAT come from experiments in which FGF21 is pharmacologically administered or overexpressed in obese rodents, revealing potent effects on the amelioration of the metabolic profile during obesity (4, 60). The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.